Scholarlink

Background <p><i>Polo-like kinase 4 (PLK4) </i>has been shown to be a tumor-promoting factor with multiple impacts on cancer growth, invasiveness, and treatment sensitivity. The current study aimed to investigate the expression of <i>PLK4</i> in diffuse large B-cell lymphoma (DLBCL) versus control tissues and its relationship with disease features and prognosis in DLBCL patients undergoing R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) treatment.</p> Methods <p>Ninety-seven DLBCL patients who received R-CHOP treatment were retrospectively included, and the lesion tissue was retrieved and subjected to quantitative polymerase chain reaction (qPCR) for PLK expression determination. Another 30 control tissues (reactive lymphoid tissue) were also subjected to qPCR.</p> Results <p><i>PLK4</i> expression was greater in DLBCL tissue than in reactive lymphoid tissue (nearly 3-fold change, <i>P</i> &lt; 0.001). <i>PLK4</i> in DLBCL was correlated with increased Ann Arbor stage (<i>P</i> = 0.038), lactate dehydrogenase abnormality (<i>P</i> = 0.031), international prognostic index (IPI) score (<i>P</i> = 0.002) and IPI risk stratification (<i>P</i> = 0.001). After cutoff by quartiles, <i>PLK4</i> ≥ 50% quantile (<i>P</i> = 0.040) and <i>PLK4</i> ≥ 75% quantile (<i>P</i> = 0.021) were correlated with shorter progression-free survival (PFS), but <i>PLK4</i> ≥ 25% quantile was not (<i>P</i> = 0.236); <i>PLK4</i> ≥ 25% quantile (<i>P</i> = 0.349), <i>PLK4</i> ≥ 50% quantile (<i>P</i> = 0.126), and <i>PLK4</i> ≥ 75% quantile (<i>P</i> = 0.090) were not correlated with overall survival (OS). Moreover, threshold by best cutoff value (3.755), <i>PLK4</i> &gt; 3.755 was correlated with both worse PFS (<i>P</i> = 0.002) and OS (<i>P</i> = 0.036). After adjustment via multivariate Cox regression, <i>PLK4</i> &gt; 3.755 was independently correlated with PFS (hazard ratio = 3.900, <i>P</i> = 0.023).</p> Conclusions <p>High <i>PLK4</i> expression can reflect severe disease conditions and predict poor PFS in DLBCL patients undergoing R-CHOP treatment. This study sheds a light on the potency of <i>PLK4</i> as a prognostic biomarker for DLBCL management. However, more large-sample-sized and multiple regional studies are needed for verification in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High expression of polo-like kinase 4 predicts worse progression-free survival in diffuse large B cell lymphoma patients treated with R-CHOP

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月14日

查看全文
  • Dehong Xu,
  • Qijie Ran,
  • Biao Xu,
  • Qi Wang,
  • Tao Geng

摘要

Background

Polo-like kinase 4 (PLK4) has been shown to be a tumor-promoting factor with multiple impacts on cancer growth, invasiveness, and treatment sensitivity. The current study aimed to investigate the expression of PLK4 in diffuse large B-cell lymphoma (DLBCL) versus control tissues and its relationship with disease features and prognosis in DLBCL patients undergoing R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) treatment.

Methods

Ninety-seven DLBCL patients who received R-CHOP treatment were retrospectively included, and the lesion tissue was retrieved and subjected to quantitative polymerase chain reaction (qPCR) for PLK expression determination. Another 30 control tissues (reactive lymphoid tissue) were also subjected to qPCR.

Results

PLK4 expression was greater in DLBCL tissue than in reactive lymphoid tissue (nearly 3-fold change, P < 0.001). PLK4 in DLBCL was correlated with increased Ann Arbor stage (P = 0.038), lactate dehydrogenase abnormality (P = 0.031), international prognostic index (IPI) score (P = 0.002) and IPI risk stratification (P = 0.001). After cutoff by quartiles, PLK4 ≥ 50% quantile (P = 0.040) and PLK4 ≥ 75% quantile (P = 0.021) were correlated with shorter progression-free survival (PFS), but PLK4 ≥ 25% quantile was not (P = 0.236); PLK4 ≥ 25% quantile (P = 0.349), PLK4 ≥ 50% quantile (P = 0.126), and PLK4 ≥ 75% quantile (P = 0.090) were not correlated with overall survival (OS). Moreover, threshold by best cutoff value (3.755), PLK4 > 3.755 was correlated with both worse PFS (P = 0.002) and OS (P = 0.036). After adjustment via multivariate Cox regression, PLK4 > 3.755 was independently correlated with PFS (hazard ratio = 3.900, P = 0.023).

Conclusions

High PLK4 expression can reflect severe disease conditions and predict poor PFS in DLBCL patients undergoing R-CHOP treatment. This study sheds a light on the potency of PLK4 as a prognostic biomarker for DLBCL management. However, more large-sample-sized and multiple regional studies are needed for verification in the future.